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Abstract 1 
   Genome-wide association studies (GWAS) have identified loci for erythrocyte traits in 2 
primarily European ancestry populations. We conducted GWAS meta-analyses of six 3 
erythrocyte traits in 71,638 individuals from European, East-Asian, and African ancestries 4 
using a Bayesian approach to account for heterogeneity in allelic effects and variation in the 5 
structure of linkage disequilibrium between ethnicities. We identified seven novel loci for 6 
erythrocyte traits including a novel locus (RBPMS/GTF2E2), associated with mean 7 
corpuscular hemoglobin and mean corpuscular volume. Statistical fine-mapping at this locus 8 
pointed to the RBPMS gene at this locus and excluded the nearby GTF2E2 gene. Using 9 
zebrafish morpholino to evaluate loss-of-function, we observed a strong in vivo erythropoietic  10 
effect for RBPMS but not for GTF2E2, supporting the statistical fine-mapping at this locus, 11 
and demonstrating that RBPMS is a novel regulator of erythropoiesis. Our findings show the 12 
utility of trans-ethnic GWAS for discovery and characterization of genetic loci influencing 13 
hematologic traits. 14 
  15 
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Introduction 1 
     Erythrocytes disorders are common world-wide, contributing to substantial morbidity and 2 
mortality.1 Erythrocyte counts and indices are heritable (estimated h2 = 0.40-0.90 2–4), exhibit 3 
different patterns across ethnic groups, and have been influenced by selection in various 4 
ethnic groups, most notably for protection against infection against parasites such as those 5 
that cause malaria.5–7 Erythrocyte traits have been studied most extensively in European 6 
ancestry populations,8–10 and smaller studies in non-European populations have shown both 7 
shared and distinct genetic loci influencing erythrocyte traits.11,12  8 
 9 
     Trans-ethnic meta-analysis of genome-wide association studies (GWAS) data offers 10 
improved signal detection in a combined meta-analysis when heterogeneity of allelic effects, 11 
allele frequencies and differences in linkage disequilibrium (LD) between ethnicities are 12 
accounted for. Trans-ethnic meta-analysis can also enable fine-mapping of association 13 
intervals by evaluating differences in LD structure between diverse populations, thereby 14 
enhancing the detection of causal variants.13  15 
 16 
     We conducted trans-ethnic GWAS meta-analyses with the goal of elucidating the genetic 17 
architecture of erythrocyte traits, to evaluate whether: (i) combining data across populations 18 
of diverse ancestry may improve power to detect associations for erythrocyte traits; and (ii) 19 
differences in LD structure can be exploited to identify causal variants driving the observed 20 
associations with common SNPs. In this study, we analyzed GWAS summary statistics from 21 
72,630 individuals from three diverse populations of European (EUR), East Asian (EAS), and 22 
African (AFR) ancestry. We conducted replication analyses in independent samples and 23 
performed functional testing to support our approach to fine-mapping.  24 
 25 
 26 
 27 
 28 
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 1 
Subjects and Methods 2 
 3 
Study samples 4 
   We aggregated HapMap-imputed GWAS results from 71,638 individuals represented in 5 
several cohorts embedded in the CHARGE Consortium (40,258 individuals of EUR 6 
ancestry), the RIKEN / BioBank Japan Project and AGEN cohorts (15,252 individuals of EAS 7 
ancestry), and the COGENT Consortium (16,128 individuals of AFR ancestry). Phenotypic 8 
information on all participating cohorts is provided in Table S1 and has been reported 9 
previously.8,11,12,14,15  We conducted replication analyses of novel trait-loci associations in six 10 
independent studies: the Gutenberg Health Study (GHS cohorts 1 and 2, both EUR 11 
ancestry), the Genes and Blood-Clotting  Study (GBC, EUR ancestry), the NEO study (EUR 12 
ancestry) , the JUPITER trial (EUR ancestry), and the HANDLS study (AFR ancestry) 16–21 13 
(total replication size N= 16,389).   14 
 15 
Erythrocyte phenotype modelling 16 
     We analyzed six erythrocyte traits; hemoglobin concentration (Hb, g/dL), hematocrit (Hct, 17 
percentage), mean corpuscular hemoglobin (MCH, picograms), mean corpuscular 18 
hemoglobin concentration (MCHC, g/dL), mean corpuscular volume (MCV, femtoliters), and 19 
red blood cell count (RBC, 1M cells/cm3). Trait units were harmonized across all studies. 20 
MCH, MCHC, MCV and RBC were transformed to obtain normal distributions. We excluded 21 
samples deviating more than 3 SD from the ethnic and trait specific mean within each 22 
contributing study, because we focused on determinants of variation in the general 23 
population rather than on specific hematological diseases which are overrepresented at the 24 
extremes of the trait distribution (Table S2). 25 
 26 
 27 
 28 
Van Rooij et al. - Transethnic Erythrocyte GWAS 
 
8 
 
Statistical analyses 1 
   For the initial GWA analyses, cohorts used linear regression or linear mixed models to 2 
assess the association of the SNPs meeting the quality control criteria with each of the six 3 
traits. An additive genetic model was used and the regressions were adjusted for age, sex 4 
and study site, if applicable (Appendix). 5 
 6 
   For the ethnic-specific meta-analyses, GWAS results of SNPs with a minor allele 7 
frequency (MAF) ≥1% were analyzed in a fixed-effect meta-analysis (METAL software22) 8 
within each ancestry group, with genomic control (GC) correction of the individual GWAS 9 
results of each contributing cohort and the final meta-analysis results.23  10 
 11 
   For the trans-ethnic meta-analyses, the three sets of the ethnic-specific meta-analysis 12 
summary statistics were then combined with three approaches. First, fixed effects meta-13 
analyses of the three sets of ethnic-specific summary results were conducted, with GC 14 
correction of the final trans-ethnic meta-analysis results. Secondly, the three ethnic-specific 15 
data sets were combined using MANTRA (Meta-Analysis of Trans-ethnic Association 16 
studies),24 which uses a Bayesian algorithm, allowing for heterogeneity in allelic effects 17 
arising as a result of variation in LD structure across different ancestry groups. Finally, the 18 
three sets of ethnic-specific results were analyzed by means of the Han and Eskin RE2 19 
model, a meta-analysis method developed for higher statistical power under heterogeneity.25  20 
 21 
     For the replication analyses, the independent replication cohorts provided linear 22 
regression results for the novel trait-locus combinations. Their results were meta-analyzed 23 
with a fixed effects inverse variance weighted method (METAL) and the RE2 methodology. 24 
Additionally, we meta-analyzed their results with the discovery data using fixed-effects, 25 
MANTRA, and RE2 methods.  26 
 27 
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     We used the MANTRA results to fine-map the regions of trait-associated index SNPs. We 1 
defined regions by identifying variants within a 1 Mb window around each index SNP (500kb 2 
upstream and 500 kb downstream).  For each SNP in a region, the posterior probability that 3 
this SNP is driving the region's association signal was calculated by dividing the SNP's BF 4 
by the summation of the BFs of all SNPs in the region. Credible sets (CS) were 5 
subsequently created by sorting the SNPs in each region in descending order based on their 6 
BF (so starting with the index SNP since this SNP has the region's largest BF by definition). 7 
Going down the sorted list, the SNPs' posterior probabilities were summed until the 8 
cumulative value exceeded 99% of the total cumulative posterior probability for all SNPs in 9 
the region. The length of a CS was expressed in base pairs. We compared 99% credible 10 
sets for the trans-ethnic results and the results of a EUR-only MANTRA analysis.13,24,26   For 11 
the MANTRA fine-mapping analyses, a less stringent threshold value of log10 BF > 5 was 12 
applied, because we wanted to include previously identified regions which may not have 13 
showed up in the more stringent MANTRA discovery analyses. 14 
 15 
ENCODE annotation 16 
   We evaluated the SNPs identified in the discovery analyses against the ENCODE Project 17 
Consortium’s database of functional elements in the K562 erythroleukemic line.27  18 
 19 
Experiments in zebrafish 20 
   To substantiate the fine-mapping of the RBPMS/GTF2E2 region biologically, we tested the 21 
effect of morpholino knockdown in zebrafish for both RBPMS and GTF2E2 orthologous 22 
genes, followed by assays of erythrocyte development. For the selected genes, gene 23 
synteny analysis was performed and peptide homology comparison and domain structure 24 
were used when no syntenic region was previously annotated. For each gene, morpholino 25 
constructs were designed incorporating information about gene structure and translational 26 
initiation sites (Gene-Tool Inc., Philomath, OR). MOs targeting each transcript, were injected into 27 
single-cell embryos at 1, 3, and 5 ng/embyo doses to find an optimal dose at which there were 28 
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minimum non-specific toxicity. Post-injection, embryos were collected at specified time points, 1 
16-18 ss, 22-26 hpf, and 48 hpf using both standard morphological features of the whole embryo 2 
and hours post-fertilization (hpf) to stage to minimize differences in embryonic development 3 
staging caused by the MO injection.
28,29
 The embryos were then assayed for hematopoietic 4 
development by whole-mount in situ hybridization and benzidine staining. For the globin 5 
transcription, developing erythrocytes in the intermediate cell mass of the embryos were assayed 6 
by embryonic β-globin 3 expression at the 16 somite stage, or 16-18 hpf.29  Further detailed 7 
methods are provided in the Appendix. 8 
 9 
Chromatin Immunoprecipitation (ChIP) and Assay for Transposase Accessible Chromatin 10 
(ATACseq) in human CD34+ cell lines 11 
   CD34+ cells were expanded and differentiated according to the detailed methods provided 12 
in the Appendix. For ChIP-seq experiments in human CD34+ cells, Gata1 (Santa Cruz 13 
sc265X), Gata2 (Santa Cruz sc9008X) and H3K27ac (Abcam ab4729) antibodies were used 14 
as described previously. ChIP-Seq and ATACseq reads were aligned to the human 15 
reference genome (hg19) and high-confidence peaks of ChIP-Seq signal were identified and 16 
analyzed. A q-value threshold of enrichment of 0.05 was used for all datasets. 17 
Detailed methods are provided in the Appendix. 18 
 19 
Evaluation in mouse crosses 20 
     To further affirm the novel trait-loci we identified, and in an attempt to further fine-map the 21 
intervals identified in our discovery analyses through cross-species comparisons, we 22 
evaluated the new loci in syntenic regions in twelve inter-strain mouse QTL crosses.30 The 23 
methods for the original mouse cross have been previously described.
30
 Mice from 12 different 24 
strains were inter-crossed and the same erythrocyte traits we have studied by GWAS were 25 
measured in peripheral blood (Appendix). 26 
 27 
 28 
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Results 1 
     We identified 44 previously reported loci 7–12,31–35  (Table S3)  and nine novel significant 2 
trait-locus associations at seven loci (P < 5x10-8  or log10BF > 6.1, Table 1). SHROOM3 was 3 
simultaneously identified in an exome chip analysis by our group in overlapping samples.36 4 
Ethnic-specific results are presented in Table S4. Regional association plots are shown for 5 
each region in Figure S1, showing ethnic-specific results, the trans-ethnic meta-analysis and 6 
plots of pairwise LD across the regions for EUR, EAS and AFR ancestry.  7 
 8 
      Five of the novel trait-loci showed a significant association in the fixed-effects trans-9 
ethnic METAL analyses, in the Bayesian MANTRA analyses, and in the RE2 analyses;  10 
these were TMEM163/ACMSD for Hct, PLCL2:rs2060597 for MCH, and ID2, 11 
PLCL2:rs9821630, and RBPMS for MCV. Two loci (MET and FOXS1) showed a borderline 12 
significant effect in METAL and RE2, and a strong significant effect in MANTRA for HB and 13 
MCV respectively. The association of rs2979489 (RBPMS) further showed a strong 14 
association with MCH in the multi-ethnic Bayesian meta-analysis and in the RE2 model, but 15 
was not detected in the multi-ethnic fixed-effects meta-analysis, nor in any of the ethnic-16 
specific meta-analyses for this trait. Interestingly, MCH and MCV are correlated traits, yet 17 
strong heterogeneity of effect was observed for this SNP’s association with MCH only, as 18 
indicated by both METAL (I2 statistic 94%, P value Cochran’s Q statistic of heterogeneity 19 
6.48 x 10-8) and MANTRA (posterior probability of heterogeneity = 1) (Table 1). Inspection of 20 
the discovery data sets showed that one of the African-American cohorts supplied data for 21 
MCV but not for MCH, which resulted in a stronger positive association of rs2979489 with 22 
MCH than with MCV in the AFR meta-analyses. This phenomenon was accompanied by 23 
greater evidence of heterogeneity for MCH in the trans-ethnic meta-analyses because the 24 
EUR and EAS associations were in the opposite direction to that observed in the AFR meta-25 
analysis. The MANTRA and RE2 analyses were able to account for this heterogeneity, and 26 
thus yield a stronger result as compared to METAL for this trait-locus.  27 
 28 
Van Rooij et al. - Transethnic Erythrocyte GWAS 
 
12 
 
Replication analyses 1 
     In the meta-analyses of the replication cohorts the trait-SNP combinations HT-2 
TMEM163/ACMSD and MCH-RBPMS achieved a Bonferroni-corrected significance 3 
threshold with both fixed effects and RE2 methods (p<0.05/9). ID2 was Bonferroni-significant 4 
in the fixed-effects model and nominally significant in the RE2 model. Furthermore, we found 5 
nominal significance for MCV-RBPMS (fixed-effects analyses) and FOXS1 (fixed-effects and 6 
RE2) (Table S5).  7 
   When we compared the discovery and replication combined meta-analyses with the 8 
discovery analyses alone, we observed stronger associations for Hct-TMEM163/ACMSD, 9 
MCH-PLCL2, MCV-ID2, and MCV-RBPMS in all three models (fixed-effects, MANTRA and 10 
RE2). For MCH-RBPMS, we found a stronger association in the fixed-effects analysis.(Table 11 
S6). 12 
 13 
Statistical finemapping 14 
     We found that 31 trait-specific trans-ethnic 99% CSs showed a decrease in length of at 15 
least 50% as compared to their EUR only CS counterparts (26 unique loci across the six 16 
erythrocyte traits) (Table S7).  17 
     Among the novel loci identified in this study, the chromosome 8 RBPMS locus showed 18 
fine-mapping according to this criterion (Table 2, Figure 1). For MCH, the EUR credible set 19 
spanned 204,200bp, encompassing the RBPMS and GTF2E2 genes. The multi-ethnic 20 
credible set comprised just one SNP, rs2979489, within the first intron of the RBPMS gene 21 
(Figure 1).   Remarkably, this associated SNP rs2979489 is located adjacent to a GATA-22 
motif where a gradual switch of binding from GATA2 to GATA1 takes place during 23 
commitment of human CD34 progenitors towards erythroid lineage (Figure 2, Bottom left 24 
Panel). Moreover, an assay for chromatin accessibility sites (ATAC-seq) and H3K27a ChIP-25 
seq clearly identify that the genomic region proximal to this SNP is actively regulated during 26 
human erythroid differentiation (Figure 2, Bottom right Panel).  27 
 28 
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     Among the known loci, fine mapping narrowed signals as shown in Table S7. 1 
Interestingly, trans-ethnic fine-mapping of the XRN1 locus (MCH) led us to the rs6791816 2 
polymorphism. Van der Harst et al also identified the same SNP in their exploration of 3 
nucleosome-depleted regions (NDRs, representing active regulatory elements for erythropoeisis) 4 
in a follow-up analysis of their GWAS results.
10
 By means of subsequent Formaldehyde-Assisted 5 
Isolation of Regulatory Elements followed by next-generation sequencing (FAIRE-seq), they 6 
pinpointed rs6791816 as an NDR SNP in LD with their initial index SNP for MCH and MCV.   7 
   Furthermore, fine-mapping of both the MPND locus (MCH) and SH3GL1 locus (MCV) pointed 8 
to the rs8887 SNP within the 3’UTR of PLIN4. The rs8887 SNP minor allele has been shown 9 
experimentally to create a novel seed site for miR-522, resulting in decreased PLIN4 10 
expression.
37
 Furthermore, miR-522 is an expressed miRNA in circulating blood.
38
 These data 11 
suggest that an allele-specific miR-522 regulation of PLIN4 by rs8887 could serve as a functional 12 
mechanism underlying the identified association. 13 
   We additionally showed fine mapping in several other intervals (Table S7) with fine-14 
mapped genes about which less is known about their potential biologic role in erythropoeisis 15 
or red blood cell function. These regions are of interest for further hypothesis generation 16 
based upon the GWAS findings. 17 
 18 
ENCODE analyses 19 
     We further evaluated the SNPs from the chromosome 8 RBPMS region against the 20 
ENCODE Project Consortium’s database of numerous functional elements in the K562 21 
erythroleukemic line.27 The lone SNP that was fine mapped at the locus, rs2979489, was 22 
found in a strong enhancer element as defined by Segway, supporting a functional role for 23 
this SNP and the RBPMS gene. The other SNPs in the RBPMS region, excluded by the 24 
statistical fine-mapping exercise, were not annotated as regulatory in the ENCODE data 25 
(Table S8). 26 
 27 
Experiments in zebrafish 28 
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     We identified a novel erythropoietic effect for the zebrafish rbpms gene. Both embryonic 1 
globin expression at 16 somite stage and o-dianisidine/benzidine staining at 48 hours post 2 
fertilization significantly decreased in morphants, indicating a decrease in both globin 3 
transcription and Hb levels (Figure 3). This loss-of-function finding is consistent with a 4 
decreased mean erythrocyte Hb content observed in our human association results. In 5 
zebrafish, the rbpms orthology mapping included rbpms2a, rbpms2b and rbpms, and loss-of-6 
function phenotypes of all orthologs were tested experimentally. The results suggested a 7 
clear erythropoietic effect with limited functional compensation of the genes in the rbpms 8 
family in zebrafish during embryonic erythropoiesis. On the other hand, morpholino 9 
knockdown experiments with the zebrafish ortholog of the GTF2E2 gene did not show an 10 
apparent erythropoietic effect.  11 
 12 
     Review of the human association results showed no evidence of pleiotropy across the 13 
RBPMS family of genes and denote that the human association is specific to RBPMS 14 
(Supplemental Data). This review was conducted because the orthology in the fish led to 15 
inclusion of rbpms2 in the zebrafish analyses as well. These findings indicate that the 16 
statistical fine-mapping was useful to home in on RPBMS as a causal gene influencing 17 
erythropoiesis. 18 
 19 
Evaluation in mouse crosses 20 
   In the eight novel regions from our discovery analysis, six had evidence of cross-species 21 
validation by evidence of syntenic gene within the linkage peak in the mouse QTL results 22 
(Table 3). However, the human GWAS intervals were not narrowed by the mouse QTL 23 
results for any of these loci (Table S9).  24 
 25 
Discussion 26 
   We conducted GWASs and meta-analyses of six erythrocyte traits (Hb, Hct, MCH, MCHC, 27 
MCV, and RBC) in 71,638 individuals from European, Asian, and African-American ancestry. 28 
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While prior genome-wide association studies have identified loci associated with erythrocyte 1 
traits through the analysis of ancestrally homogenous cohorts and consortia, largely biased 2 
towards European ancestry studies, trans-ethnic analysis has not previously been performed 3 
while accounting for differences in genetic architecture in ethnically diverse groups. 4 
   We identified seven novel loci for erythrocyte traits (nine locus-trait combinations) and 5 
replicated 44 previously identified loci. We fine-mapped several known and new loci. One 6 
fine-mapped locus led us to a region on chromosome  8 associated with MCH and MCV.     7 
 8 
   In the chromosome 8 RBPMS/GTF2E2 locus, the index variant rs2979489, which was 9 
associated with MCV and MCH and highlighted in the trans-ethnic fine-mapping analyses, is 10 
located within the first intron of the RBPMS (RNA binding protein with multiple splicing) gene, 11 
notably at an open chromatin site at which a switch of GATA1/2 binding occurs during erythroid 12 
differentiation. The RBPMS protein product regulates a variety of RNA processes, including pre-13 
mRNA splicing, RNA transport, localization, translation, and stability.
39,40
 The RBPMS gene is 14 
expressed at relatively low levels in mammalian erythroblasts and the protein product has not 15 
been detected in mature human erythrocytes.
41,42
 16 
  17 
  The rs2979489 polymorphism showed remarkable high heterogeneity in effect on the MCH 18 
trait across the different ethnicities, with different directions of effect for the AFR meta-19 
analysis results compared to the EUR and ASN findings. If the variant is causal, this pattern 20 
of association could reflect gene-environment interaction. In this case different exposures in 21 
AFR compared to EUR/ASN populations may lead to a marginal effect of the SNP in 22 
opposing directions by different selection pressures. If however rs2979489 is not causal, but 23 
rather a marker in LD with the causal variant, then the opposing direction of effects could 24 
reflect very different LD structures in the different populations, also indicating selection, or 25 
theoretically it could even reflect different causal variants in AFR and EUR/EAS - and 26 
rs2979489 being just in strong LD with both causal variants. 27 
 28 
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   The SNP rs2979489 is located adjacent to a GATA-motif where a gradual switch of binding 1 
from GATA2 to GATA1 takes place during commitment of human CD34 progenitors towards 2 
erythroid lineage. These observations suggest that rs2979489 localize at a potential 3 
regulatory site where a modulation of erythroid cell differentiation occurs and the presence of 4 
rs2979489 may lead to observed red cell trait alterations in human populations, possibly 5 
through regulation of RBPMS gene expression timing, level, and/or splicing variation. 6 
Although RBPMS previously had no known role in haematopoiesis or more specifically in 7 
erythropoiesis, RBPMS has been previously shown to be upregulated in transcriptional 8 
profiles of murine and human hematopoietic stem cells.43–45 Its role may be at much earlier 9 
stages during the differentiation of erythrocytes from erythroblasts and/or hematopoietic 10 
stem cells. RBPMS is known to physically interact with Smad2, Smad3, and Smad4 and 11 
stimulate smad-mediated transactivation through enhanced Smad2 and Smad3 12 
phosphorylation and associated promotion of nuclear accumulation of Smad proteins.46  13 
These SMAD proteins are known to regulate the TGF-β mediated regulation of 14 
hematopoietic cell fate and erythroid differentiation.47  RBPMS has four annotated transcript 15 
isoforms, and further delineation of the tissue-specificity, timing of expression, and function 16 
of these transcripts in the context of the genetic variant we identified warrants further study.  17 
 18 
   Among the additional six loci, we identified two loci in which the index SNP was located 19 
within annotated genes, rs6430549 in ACMSD (aminocarboxymuconate semi aldehyde 20 
decarboxylase, intronic and rs2299433 in MET (mesenchymal epithelial transition factor, 21 
intronic). No previous hematologic role has been described for both regions. Variants in the 22 
chromosome 2q21.3 ACMSD region have previously been associated with blood metabolite 23 
levels, obesity and Parkinson’s Diseases.
48–50
  A genetic variant in the first intron of the MET 24 
gene was significantly associated with both Hb and Hct; however association was not 25 
observed in replication samples possibly due to lower power in the replication experiment.  26 
Three additional loci were intergenic but close to a coding gene (rs10929547 near ID2 27 
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(inhibitor of DNA binding 2, dominant negative helix-loop-helix protein) and rs6121246 near 1 
FOXS1 (forkhead box S1), and rs2060597 approximately 40 kbp upstream of the PLCL2 2 
(phospholipase C-like 2) gene). The roles of variants in these regions in determining 3 
erythrocyte traits are unknown.41,51    4 
 5 
   In the statistical fine-mapping analyses, the trans-ethnic meta-analysis approach resulted 6 
in smaller 99% credible intervals in all of the novel loci identified in this study.  Since these 7 
loci were identified in analyses that accounted for heterogeneity in allelic effects between 8 
ethnic groups, in which the heterogeneity may be due to variation in LD patterns, we 9 
examined the LD patterns in these loci. Not surprisingly, we noted that the consistent 10 
decrease in the size of 99% credible interval across all loci is likely due to the inclusion of 11 
cohorts of African ancestry, an ethnic group with generally smaller LD blocks throughout the 12 
genome. The loss-of-function screens in zebrafish for the chromosome 8 signal suggested 13 
that these analyses successfully identified a single gene (RBPMS) with erythropoietic effect 14 
within one of the fine-mapped intervals. We also fine-mapped previously known regions such 15 
as the chromosome 6p21.1 region associated with RBC count, highlighted CCND3, which 16 
has been experimentally shown to regulate RBC count experimentally in a knock-out mouse 17 
model.52 These examples suggest that attempts to refine association signals using these 18 
types of approaches in existing samples may yield functional candidates for further 19 
mechanistic hypothesis testing, which is a major goal of GWAS. 20 
 21 
Trans-ethnic genome-wide meta-analyses of common variants have aided in the 22 
characterization of genetic loci for various complex traits.13,53–55 Our data demonstrate the 23 
benefits of trans-ethnic genome-wide meta-analysis in identifying and fine-mapping genetic 24 
loci of erythrocyte traits. By exploiting the differences in genetic architecture of the 25 
associations within these loci in various ethnic groups, we may identify causal genes 26 
influencing clinically relevant hematologic traits. Use of a similar approach for other complex 27 
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traits is likely to provide deeper insights into the biological mechanisms underlying human 1 
traits. 2 
  3 
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Appendix 1 
Genotyping 2 
In brief, the cohorts comprise unrelated individuals, except for the Framingham Heart Study 3 
(related individuals of European ancestry) and GeneSTAR (related individuals of European 4 
or African ancestry). SNPs with a minor allele frequency < 1%, missingness >5% or HWE P 5 
< 10-7 were excluded. Genotypes were imputed to approximately 2.5 million SNPs using 6 
HapMap Phase II CEU. The RIKEN and the BioBank Japan Project and AGEN cohorts 7 
comprise unrelated individuals of East-asian ancestry (EAS). SNPs with a minor allele 8 
frequency < 0.01, missingness >1% or HWE P < 10-7 were excluded. Individuals with a call 9 
rate < 98% were excluded as well. Genotypes were imputed to approximately 2.5 million 10 
SNPs using HapMap Phase II JPT and CHB. The COGENT consortium cohorts comprise 11 
individuals of African-American ancestry (AFR). SNPs with a minor allele frequency < 1% or 12 
missingness >10% were excluded. Genotypes were imputed to approximately 2.5 million 13 
SNPs using HapMap Phase II CEU and YRI. 14 
 15 
Cohort specific GWAS 16 
Each cohort used linear regression to assess the association of all SNPs meeting the quality 17 
control criteria with each of the six traits separately. An additive genetic model was used and 18 
the regressions were adjusted for age, sex and study site (if applicable). The Framingham 19 
Heart Study and the GeneSTAR study used linear mixed effects models to account for 20 
relatedness, and these models included adjustment for principal components(address 21 
stratification comment). Multi-center studies adjusted for study site. 22 
 23 
Ethnic-specific GWAS meta-analyses  24 
We performed three ethnic-specific GWAS fixed effects inverse variance-weighted meta-25 
analyses for each trait using METAL software.22 SNPs with an imputation quality < 30% 26 
were excluded and study results were adjusted for genomic inflation factors.23   27 
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 1 
Trans-ethnic meta-analyses 2 
For each trait we performed a trans-ethnic fixed-effect inverse variance-weighted meta-3 
analysis of the EUR, EAS, and AFR GWAS summary statistics using METAL. The ethnic-4 
specific GWAS summary statistics were also combined using the MANTRA (Meta-Analysis 5 
of Trans-ethnic Association Studies) package, a meta-analysis software tool allowing for 6 
heterogeneity in allelic effects due to differences in LD structure in different ancestry 7 
clusters.24 MANTRA results are reported as log10 Bayes's factors (log10BF). The three sets 8 
of ethnic-specific results were furthermore analysed by means of the Han and Eskin RE2 9 
model, a meta-analysis method developed for higher statistical power under heterogeneity.25 10 
We used the METASOFT 3.0c tool as developed by the Buhm Han laboratories 11 
(http://www.buhmhan.com/home) . For the fixed-effects and the RE2 models we applied a 12 
genome-wide significant threshold value of P< 5E-08, given the traits under investigation are 13 
correlated (Table S10). For the MANTRA discovery analyses, a log10BF > 6.1 was 14 
considered as a genome-wide significant threshold value.56 15 
 16 
Replication in human cohorts 17 
   The six independent replication studies: the Gutenberg Health Study (GHS cohorts 1 and 2, 18 
both EUR ancestry), the Genes and Blood-Clotting  Study (GBC, EUR ancestry), the NEO study 19 
(EUR ancestry) , the JUPITER trial (EUR ancestry), and the HANDLS study (AFR ancestry) 
16–21
 20 
(total replication size N= 16,389) provided linear regression results for the novel trait-locus 21 
combinations. Their results were meta-analyzed with a fixed effects inverse variance 22 
weighted method (METAL) and the RE2 methodology. Additionally, we meta-analyzed 23 
replication results with the discovery data using fixed-effects, MANTRA, and RE2 methods. 24 
For the replication analyses of the nine individual trait–locus combinations we applied a 25 
threshold of P<0.05/9. Additional human replication findings are provided in Supplemental 26 
Data. 27 
 28 
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Fine-mapping 1 
We used the MANTRA results to fine-map the regions of trait associated index SNPs. We 2 
defined regions by identifying variants within a 1 Mb window around each index SNP (500kb 3 
upstream and 500 kb downstream).  For each SNP in a region, the posterior probability that 4 
this SNP is driving the region's association signal was calculated by dividing the SNP's BF 5 
by the summation of the BFs of all SNPs in the region. Credible sets (CS) were 6 
subsequently created by sorting the SNPs in each region in descending order based on their 7 
BF (so starting with the index SNP since this SNP has the region's largest BF by definition). 8 
Going down the sorted list, the SNPs' posterior probabilities were summed until the 9 
cumulative value exceeded 99% of the total cumulative posterior probability for all SNPs in 10 
the region. The length of a CS was expressed in base pairs. We compared 99% credible 11 
sets for the trans-ethnic results and the results of a EUR-only MANTRA analysis.13,24,26   For 12 
the MANTRA fine-mapping analyses, a less stringent threshold value of log10 BF > 5 was 13 
applied, because we wanted to include previously identified regions which may not have 14 
showed up in the more stringent MANTRA discovery analyses. 15 
 16 
Heterogeneity analysis 17 
Heterogeneity of the associations across the different ethnicities was assessed by the I2 and 18 
Cochran’s Q statistics as reported by METAL22 , and the posterior probability of 19 
heterogeneity as reported by MANTRA.24 20 
 21 
Zebrafish gene loss-of-function experiments 22 
Zebrafish rbpms, rbpms2 and gtf2e2 were identified and confirmed by peptide sequence 23 
homology study and gene synteny analysis. For rbpms, we relied solely on peptide 24 
homology comparison and domain structure since no syntenic region was previously 25 
annotated and found by this study. For each morpholino (MO) its design incorporated 26 
information about gene structure and translational initiation sites (Gene-Tool Inc., Philomath, 27 
OR). MOs targeting each transcript, were injected into single-cell embryos at 1, 3, and 5 28 
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ng/embyo doses to find an optimal dose at which there were minimum non-specific toxicity. 1 
The step-wise doses also give a range of phenotypes from a hypomorph to a near complete 2 
knockdown for most transcripts, which were used to assess the model of an additive model 3 
of genetic association. Post-injection, embryos were collected at specified time points, 16-18 4 
ss, 22-26 hpf, and 48 hpf using both standard morphological features of the whole embryo 5 
and hours post-fertilization (hpf) to stage to minimize differences in embryonic development 6 
staging caused by the MO injection.28,29 The embryos were then assayed for hematopoietic 7 
development by whole-mount in situ hybridization and benzidine staining. We conducted two 8 
assays simultaneously for globin transcription and hemoglobin formation. For the globin 9 
transcription, developing erythrocytes in the intermediate cell mass of the embryos were 10 
assayed by embryonic β-globin 3 expression at the 16 somite stage, or 16-18 hpf.29 11 
Benzidine staining phenotype was categorized from subtle decrease to complete absence of 12 
staining, which was categorized as mild, intermediate or strong effect. Morphologically 13 
normal morphants with decreased blood formation were scored for hematopoietic effect. 14 
 15 
In zebrafish, the rbpms gene was not annotated in the known EST and cDNA databases, 16 
although a genomic sequence in the telomeric region on chromosome 7 predicting a coding 17 
sequence (80% peptide sequence similarity) was identified. In addition, the synteny between 18 
human RBPMS and GTF2E2 genes is not conserved in zebrafish where rbpms and gtf2e2 19 
are located on two separate chromosomes, chromosome 7 and 1, respectively. The rbpms2 20 
gene was annotated with two paralogs on chromosome 7 (26 Mb away from and centromeric 21 
to the true rbpms gene) and chromosome 25 of the zebrafish genome. This orthology 22 
mapping was confirmed again by this research based on gene synteny and 88 and 91% 23 
sequence similarity, respectively for rbpms2b and rbpms2a to the human RBPMS2 gene. 24 
These two zebrafish RBPMS2 orthologs have a higher overall sequence similarity to the 25 
human RBPMS gene than the true zebrafish rbpms, but both have a RBPMS2-signature 26 
stretch of Alanine in the C-terminus of the protein. Therefore, to confirm our rbpms orthology 27 
study, and to confirm functional conservation of rbpms gene in zebrafish, MO individual 28 
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knockdown of both rbpms2a and rbpms2b was also performed in independent experiments, 1 
showing much less or no effect by rbpms2a knock-down and moderate effect by rbpms2b 2 
impact on erythropoiesis, suggesting functional compensation of the genes in the rbpms 3 
family in zebrafish during embryonic erythropoiesis.  4 
 5 
Chromatin Immunoprecipitation (ChIP) 6 
For ChIP-seq experiments the following antibodies were used: Gata1 (Santa Cruz sc265X), 7 
Gata2 (Santa Cruz sc9008X) and H3K27ac (Abcam ab4729). ChIP experiments were 8 
performed as previously described with slight modifications.57,58 Briefly, 20-30 million cells for 9 
each ChIP were crosslinked by the addition of 1/10 volume 11% fresh formaldehyde for 10 10 
min at room temperature. The crosslinking was quenched by the addition of 1/20 volume 11 
2.5M Glycine. Cells were washed twice with ice-cold PBS and the pellet was flash-frozen in 12 
liquid nitrogen. Cells were kept at -80°C until the experiments were performed. Cells were 13 
lysed in 10 ml of Lysis buffer 1 (50 mM HEPES-KOH, pH 7.5, 140 mM NaCl, 1 mM EDTA, 14 
10% glycerol, 0.5% NP-40, 0.25% Triton X-100, and protease inhibitors) for 10 min at 4C. 15 
After centrifugation, cells were resuspended in 10 ml of Lysis buffer 2 (10 mM Tris-HCl, pH 16 
8.0, 200 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, and protease inhibitors) for 10 min at room 17 
temperature. Cells were pelleted and resuspended in 3 ml of Sonication buffer for K562 and 18 
U937 and 1 ml for other cells used (10 mM Tris-HCl, pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.5 19 
mM EGTA, 0.1% Na-Deoxycholate, 0.05% Nlauroylsarcosine, and protease Inhibitors) and 20 
sonicated in a Bioruptor sonicator for 24-40 cycles of 30s followed by 1min resting intervals. 21 
Samples were centrifuged for 10 min at 18,000 g and 1% of TritonX was added to the 22 
supernatant. Prior to the immunoprecipitation, 50 ml of protein G beads (Invitrogen 100-04D) 23 
for each reaction were washed twice with PBS, 0.5% BSA twice. Finally the beads were 24 
resuspended in 250 ml of PBS, 0.5% BSA and 5 mg of each antibody. Beads were rotated 25 
for at least 6 hr at 40C and then washed twice with PBS, 0.5% BSA. Cell lysates were added 26 
to the beads and incubated at 40C overnight. Beads were washed 1x with (20 mM Tris-HCl 27 
(pH 8), 150 mM NaCl, 2mM EDTA, 0.1% SDS, 1%Triton X-100), 1x with (20 mM Tris-HCl 28 
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(pH 8), 500 mM NaCl, 2 mM EDTA, 0.1% SDS, 1%Triton X-100), 1x with (10 mM Tris-HCl 1 
(pH 8), 250 nM LiCl, 2 mM EDTA, 1% NP40) and 1x with TE and finally resuspended in 200 2 
ml elution buffer (50 mM Tris-Hcl, pH 8.0, 10 mM EDTA and 0.5%–1% SDS) Fifty microliters 3 
of cell lysates prior to addition to the beads was kept as input. Crosslinking was reversed by 4 
incubating samples at 65°C for at least 6 hr. Afterwards the cells were treated with RNase 5 
and proteinase K and the DNA was extracted by Phenol/Chloroform extraction. 6 
 7 
ChIP-Seq library Preparation 8 
Briefly, ChIP-Seq libraries were prepared using the following protocol. End repair of 9 
immunoprecipitated DNA was performed using the End-It DNA End-Repair kit (Epicentre, 10 
ER81050) and incubating the samples at 25°C for 45 min. End repaired DNA was purified 11 
using AMPure XP Beads (1.8X of the reaction volume) (Agencourt AMPure XP – PCR 12 
purification Beads, BeckmanCoulter, A63881) and separating beads using DynaMag-96 13 
Side Skirted Magnet (Life Technologies, 12027). A tail was added to the end-repaired DNA 14 
using NEB Klenow Fragment Enzyme (3’-5’ exo, M0212L), 1X NEB buffer 2 and 0.2 mM 15 
dATP (Invitrogen, 18252-015) and incubating the reaction mix at 37°C for 30 min. A-tailed 16 
DNA was cleaned up using AMPure beads (1.8X of reaction volume). Subsequently, cleaned 17 
up dA-tailed DNA went through Adaptor ligation reaction using Quick Ligation Kit (NEB, 18 
M2200L) following manufacturer’s protocol. Adaptor-ligated DNA was first cleaned up using 19 
AMPure beads (1.8X of reaction volume), eluted in 100μl and then size-selected using 20 
AMPure beads (0.9X of the final supernatant volume, 90 μl). Adaptor ligated DNA fragments 21 
of proper size were enriched with PCR reaction using Fusion High-Fidelity PCR Master Mix 22 
kit (NEB, M0531S) and specific index primers supplied in NEBNext Multiplex Oligo Kit for 23 
Illumina (Index Primer Set 1, NEB, E7335L). Conditions for PCR used are as follows: 98 °C , 24 
30 sec; [98°C, 10 sec; 65 °C, 30 sec; 72 °C, 30 sec] X 15 to 18 cycles; 72°C, 5 min; hold at 4 25 
°C. PCR enriched fragments were further size selected by running the PCR reaction mix in 26 
2% low-molecular weight agarose gel (Bio-Rad, 161- 3107) and subsequently purifying them 27 
using QIAquick Gel Extraction Kit (28704). Libraries were eluted in 25μl elution buffer. After 28 
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measuring concentration in Qubit, all the libraries went through quality control analysis using 1 
an Agilent Bioanalyzer. Samples with proper size (250-300 bp) were selected for next 2 
generation sequencing using Illumina Hiseq 2000 or 2500 platform. 3 
 4 
ChIP-Seq data analysis 5 
Alignment and Visualization ChIP-Seq reads were aligned to the human reference genome 6 
(hg19) using bowtie with parameters -k 2 -m 2 -S.59 WIG files for display were created using 7 
MACS60 with parameters -w -S --space=50 --nomodel --shiftsize=200 and were displayed in 8 
IGV.61,62 9 
 10 
Peak and Bound Gene Identification 11 
High-confidence peaks of ChIP-Seq signal were identified using MACS with parameters --12 
keepdup= auto -p 1e-9 and corresponding input control. Bound genes are RefSeq genes 13 
that contact a MACS-defined peak between -10000bp from the TSS and +5000bp from the 14 
TES. 15 
 16 
Assay for Transposase Accessible Chromatin (ATACseq) 17 
CD34+ cells were expanded and differentiated using the protocol mentioned above. Before 18 
collection, cells were treated with 25 ng/ml hrBMP4 for 2 hr. 5 x 104 cells per differentiation 19 
stage were harvested by spinning at 500 x g for 5 min, 4° C. Cells were washed once with 20 
50 µL of cold 1X PBS and spinned down at 500 x g for 5 min, 4° C. After discarding 21 
supernatant, cells were lysed using 50 µL cold lysis buffer (10 mM Tris-HCl pH 7.4, 10 mM 22 
NaCl, 3 mM MgCl2, 0.1% IGEPAL CA-360) and spun down immediately at 500 x g for 10 23 
mins, 4 ºC. Then the cells were precipitated and kept on ice and subsequently resuspended 24 
in 25 µL 2X TD Buffer (Illumina Nextera kit), 2.5 µL Transposase enzyme (Illumina Nextera 25 
kit, 15028252) and 22.5 µL Nuclease-free water in a total of 50 µL reaction for 1 hr at 37° C. 26 
DNA was then purified using Qiagen MinElute PCR purification kit (28004) in a final volume 27 
of 10 µL. Libraries were constructed according to Illumina protocol using the DNA treated 28 
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with transposase, NEB PCR master mix, Sybr green, universal and library-specific Nextera 1 
index primers. The first round of PCR was performed under the following conditions: 72° C, 2 
5 min; 98° C, 30 sec; [98°C, 10 sec; 63 °C, 30 sec; 72 °C, 1 min] X 5 cycles; hold at 4°C. 3 
Reactions were kept on ice and using a 5 µL reaction aliquot, the appropriate number of 4 
additional cycles required for further amplification was determined in a side qPCR reaction: 5 
98 °C , 30 sec; [98 °C, 10 sec; 63 °C, 30 sec; 72 °C, 1 min] X 20 cycles; hold at 4 °C. Upon 6 
determining the additional number of PCR cycles required further for each sample, library 7 
amplification was conducted using the following conditions: 98°C, 30 sec; [98°C,10 sec; 8 
63°C, 30 sec; 72 °C, 1 min] X appropriate number of cycles; hold at 4°C. Libraries prepared 9 
went through quality control analysis using an Agilent Bioanalyzer. Samples with appropriate 10 
nucleosomal laddering profiles were selected for next generation sequencing using Illumina 11 
Hiseq 2500 platform. 12 
  13 
ATACseq data analysis 14 
All human ChIP-Seq datasets were aligned to build version NCBI37/HG19 of the human 15 
genome using Bowtie2 (version 2.2.1)59 with the following parameters: --end-to-end, -N0, -16 
L20. We used the MACS2 version 2.1.0 60 peak finding algorithm to identify regions of 17 
ATAC-Seq peaks, with the following parameter --nomodel --shift -100 --extsize 200. A q-18 
value threshold of enrichment of 0.05 was used for all datasets. 19 
 20 
Mouse QTL mapping  21 
The methods for the original mouse cross have been previously described.30 Briefly, mice 22 
from 12 different strains were inter-crossed30 and the same erythrocyte traits we have 23 
studied by GWAS were measured in peripheral blood. The Jackson Laboratory Animal Care 24 
and Use Committee approved all protocols. The number of markers genotyped per cross 25 
varied by the platform used, and the total number per cross is provided in Table S9. QTL 26 
analysis was performed for each erythrocyte trait using R/qtl v1.07-12 http://www.rqtl.org).63 27 
Genetic map positions of all markers used were updated to the new mouse genetic map 28 
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using online mouse map converter tool at http://cgd.jax.org.64 All phenotypic data were 1 
ranked-Z transformed to approximate the normal distribution prior to analysis. The QTL 2 
analysis was performed as a genome-wide scan with sex as an additive covariate. 3 
Permutation testing (1000 permutations) was used to determine significance, and LOD 4 
scores greater than the 95th percentile (P < 0.05) were considered significant. QTL 5 
confidence intervals were determined by the posterior probability.65,66 For each candidate 6 
region in the mouse, the coordinates were obtained from the Mouse Genome Database, 7 
which is part of Mouse Genome Informatics (MGI), using the ‘Genes and Markers'  query 8 
(http://www.informatics.jax.org/marker/). Protein coding genes, non-coding RNA genes, and 9 
unclassified genes were queried.  10 
 11 
Pleiotropy analysis   12 
   To further relate the zebrafish findings in the rbpms gene family back to the human 13 
association data and to explore possible pleiotropy which might suggest effects on an earlier 14 
hematopoietic progenitor cell, we evaluated RBPMS association with WBC traits and 15 
RBPMS2 association with RBC and WBC traits(Supplemental Data).   16 
 17 
 18 
Supplemental Data 19 
   Supplemental data include individual cohort descriptions, methods replication findings, 69 20 
tables, and 123 figures 21 
  22 
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 1 
Figure Legends 2 
 3 
Figure 1: Fine mapping of the chromosome 8 RBPMS/GTF2E2 locus.  99% credible sets 4 
(red dots) around the top hit rs2979489 (red diamond). European Ancestry MANTRA 5 
analyses (upper panels) for MCH (left) and MCV (right) are shown, compared to 99% 6 
credible sets of the multi-ethnic MANTRA analyses (bottom panels, MCH on the left and 7 
MCV on the right). 8 
Figure 2. rs2979489 is localized to a potential regulatory site that involves in transition 9 
binding of GATA 2 to GATA1 during erythrocyte differentiation. Top panel. Gene-track view 10 
of rs2979489 location in the RBPMS/GTF2E2 gene region. Bottom left Panel: Gene-track of 11 
RBPMS gene showing overlap of GATA2, GATA1 and ATACseq peaks (red, blue and green, 12 
respectively) during human erythroid differentiation. Bottom right Panel: Overlap of ATACseq 13 
(green) and H3K27ac ChIPseq (black) during differentiation at the region proximal to the SNP 14 
rs2979489. The grey horizontal line indicates the position of SNP rs 2979489. D0 - Day 0, H6 – 15 
Hour 6, D3 – Day3, D4 – Day 4 and D5 – Day 5 of erythroid differentiation time-course post-16 
induction of differentiation. 17 
Figure 3: Loss-of-function analysis of the RBPMS, RBPMS2, and GTF2E2 orthologues in 18 
zebrafish. After injection of 0-3 ng ATG- and splicing-morpholinos against the RBPMS zebrafish 19 
orthologue, o-dianisidine/benzidine staining in embryos at 48 hours post fertilization (hpf) (A-E 20 
right panels) and embryonic e3 globin expression (A-E left panels) in embryos at 16-18 somite 21 
stage (ss) are significantly decreased, indicating a dose-dependent disruption in erythropoiesis in 22 
the experimentally treated embryos as compared to controls. Representative results are shown 23 
for the RBPMS orthologue in embryos (E panel) as well as for rbpms2a (C panel) and rbpms2b 24 
(D panel) at higher doses. Injections of morpholino against the zebrafish GTF2E2 orthologue (B 25 
panel) also at a higher dose show no significant effect on e3 globin expression at 16-18 ss and 26 
o-dianisidine/benzidine staining at 48 hpf. Expression of vascular marker gene, kdrl (A-E middle 27 
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panels), is relatively normal in all morpholino-injected embryos at 24-26 hpf, suggesting grossly 1 
normal development of cells in other organs..2 
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Table 1: Novel findings from the METAL and MANTRA trans-ethnic analyses. 
       METAL  MANTRA  RE2 
Trait SNP Chr Gene c/nc  N Effect (SE) P  Log10BF posthg  P 
              
Hb rs2299433 7 MET T/C  63091 0.041 (0.008) 6.16E-08  6.195 0.027  1.20E-07 
              
Hct rs6430549 2 TMEM163 / ACMSD A/G  71647 0.103 (0.018) 4.96E-09  7.408 0.120  8.46E-09 
Hct rs2299433 7 MET T/C  63532 0.102 (0.019) 5.66E-08  6.199 0.099  9.87E-08 
              
MCH rs2060597 3 PLCL2 T/C  38836 0.006 (0.001) 4.18E-10  8.178 0.009  9.75E-10 
MCH rs2979489 8 RBPMS A/G  37531 -0.002 (0.001) 8.89E-05  9.723 1.000  1.19E-12 
              
MCV rs10929547 2 ID2 A/C  50870 -0.002 (0.0003) 2.50E-09  7.977 0.007  2.14E-09 
MCV rs9821630 3 PLCL2 A/G  48697 -0.002 (0.0004) 6.86E-09  7.864 0.004  2.44E-09 
MCV rs2979489 8 RBPMS A/G  48697 -0.002 (0.0004) 7.24E-09  7.961 0.003  1.65E-09 
MCV rs6121246 20 FOXS1 T/C  49896 0.003 (0.001) 4.05E-07  6.296 0.003  8.31E-08 
Chr = chromosome number ; c/nc = coding/non-coding allele ; N = number of participants ;  SE = standard error ; P = p-value ; Log10BF = Logaritm of Bayes Factor ; posthg = posterior probability of 
heterogeneity  
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Table 2: Fine mapping of a novel locus identified in European ancestry meta-analysis by MANTRA trans-ethnic analysis. 
        EUR   Multi-ethnic   
 Trait  Chr Gene   topSNP log10BF n_SNPs width 
(bp) 
 topSNP log10BF n_SNPs width 
(bp) 
  
              
MCH 8 RBPMS  rs2979502 6.32982 21 241480  rs2979489 9.72267 1 1  
              
MCV 8 RBPMS  rs2979489 6.13733 11 241480  rs2979489 7.96132 1 1  
                            
 
Chr = chromosome number ; Log10BF = Logaritm of Bayes Factor ; n_SNPs : number of SNPs in the region  
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Table 3 Mouse QTL validation of novel MANTRA trans-ethnic findings. 
Trait Chr Gene Human (hg18 / Build 36)  Mouse (37 mm9)  Significant (bold) and Suggestive Mouse 
QTL b 
 LOD   
   (chromosome:position)  (chromosome:position)  peak ( 95% CI) (Mb)    
          
Hct 2 TMEM163/ACMSD chr2:135196450-135438613  chr1:129581372-129711586 a 141.0 (54.8 – 158.9)  3.72 
Hct 4 SHROOM3 chr4:77586311-77629342  chr5:93112461-93394344 b 46.0 (19.6-106.5)  2.34 
Hct 7 MET chr7:116118114-116131947  chr6:17432318-17447418 a 37.6 (6.6 – 127.9)  2.75 
          
MCH 8 RBPMS chr8:30400375-30400375  chr8:34893115-35040335 
 
b 78.9 (28.0-96.1)  3.98 
MCV 3 PLCL2 chr3:16860239-16945942  chr17:50604848-50698773 a 46.0  (28.6 – 55.3)  5.46 
MCV 20 FOXS1 chr20:29684484-29897013  chr2:152576419-152758874 a 170.1 (147.6 – 179.3)  4.69 
          
 
 
 
/a within the corresponding human interval (+/- 250 kb) 
/b gene found in a significant or suggestive 95% CI mouse QTL, not corresponding to the human interval 
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